The pharmacological management of cancer pain

European Journal of Cancer

Volumn 37, Issue SUPPL. 7, 2001, Pages

  Cherny, Nathan I ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT;

BREATHING DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CHEMICALLY INDUCED DISORDER; CONSCIOUS SEDATION; DECISION MAKING; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; GASTROINTESTINAL DISEASE; HUMAN; NEOPLASM; PAIN; REVIEW; URINE RETENTION;

ANALGESICS; CENTRAL NERVOUS SYSTEM DISEASES; CONSCIOUS SEDATION; DECISION MAKING; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; GASTROINTESTINAL DISEASES; HUMANS; NEOPLASMS; PAIN; RESPIRATION DISORDERS; URINARY RETENTION;

EID: 0011390814     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)80031-9     Document Type: Article

References (88)

1. World Health Organization. Cancer Pain Relief. World Health Organization, Geneva, 1986.
2. Takeda F. Japanese field-testing of WHO guidelines. PRN Forum 1985, 4: 4-5.
3. Ventafridda V, Tamburini M, Caraceni A, De Conno F, Naldi F. A validation study of the WHO method for cancer pain relief. Cancer 1987, 59: 850-856.
4. Walker VA, Hoskin PJ, Hanks GW, White ID. Evaluation of WHO analgesic guidelines for cancer pain in a hospital-based palliative care unit. J Pain Symptom Manage 1988, 3: 145-149.
5. Schug SA, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage 1990, 5(1): 27-32.
6. Goisis A, Gorini M, Ratti R, Luliri P. Application of a WHO protocol on medical therapy for oncologic pain in an internal medicine hospital. Tumori 1989, 75: 470-472.
7. Grond S, Zech D, Schug SA, Lynch J, Lehmann KA. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991, 6: 411-422.
8. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation [see comments]. JAMA 1995, 274: 1870-1873.
9. Eisenberg E, Berkey CS, Carr DB, Mosteller F, Chalmers TC. Efficacy and safety of nonsteroidal antiinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994, 12: 2756-2765.
10. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998, 38: 97-120.
11. Lefkowith JB. Cyclooxygenase-2 specificity and its clinical implications. Am J Med 1999, 106(5B): 43S-50S.
12. Ehrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W et al. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Clin Pharmacol Ther 1999, 65: 336-347.
13. Hawkey CJ. COX-2 inhibitors. Lancet 1999, 353(9149): 307-314.
14. Bennett WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis 1996, 28(1 Suppl 1): S56-62.
15. Laine L. Nonsteroidal anti-inflammatory drug gastropathy. Gastrointest Endosc Clin N Am 1996, 6: 489-504.
16. Lehmann T, Day RO, Brooks PM. Toxicity of antirheumatic drugs. Med J Aust 1997, 166: 378-383.
17. Brooks PM, Day RO. Nonsteroidal antiinflammatory drugs-differences and similarities. N Engl J Med 1991, 324: 1716-1725.
18. Hawkey CJ. Progress in prophylaxis against nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee. Am J Med 1998, 104: 67S-74S; discussion 79-80S.
19. Valentini M, Cannizzaro R, Poletti M, Bortolussi R, Fracasso A, Testa V et al. Nonsteroidal antiinflammatory drugs for cancer pain: comparison between misoprostol and ranitidine in prevention of upper gastrointestinal damage. J Clin Oncol 1995, 13: 2637-2642.
20. Taha AS, Hudson N, Hawkey CJ, Swannell AJ, Trye PN, Cottrell J et al. Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs [see comments]. N Engl J Med 1996, 334: 1435-1439.
21. Plosker GL, Lamb HM. Diclofenac/misoprostol. Pharmacoeconomic implications of therapy. Pharmacoeconomics 1999, 16: 85-98.
22. McKenna F. Diclofenac/misoprostol: the European clinical experience. J Rheumatol Suppl 1998, 51: 21-30.
23. Makin AJ, Williams R. Acetaminophen-induced hepatotoxicity: predisposing factors and treatments. Adv Intern Med 1997, 42: 453-483.
24. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions [see comments]. Pain 1990, 43(3): 273-286.
25. Hanks GW, Forbes K. Opioid responsiveness. Acta Anaesthesiol Scand 1997, 41(1 Pt 2): 154-158.
26. Hanks GW. The clinical usefulness of agonist-antagonistic opioid analgesics in chronic pain. Drug Alcohol Depend 1987, 20: 339-346.
27. Houde RW, Wallenstein SL, Beaver WT. Evaluation of analgesics in patients with cancer pain. In: Lasagna L (Ed.), International Encycloped of Pharmacology and Therapeutics. Pergamon Press, New York, 1966, pp. 59-67.
28. Ripamonti C, Groff L, Brunelli C, Polastri D, Stravakis A, De Conno F. Switching from morphine to oral methadone in treating cancer pain. What is the equianalgesic dose ratio. J Clon Oncol 1998, 16: in press.
29. Cherny NJ, Chang V, Frager G, Ingham JM, Tiseo PJ, Popp B et al. Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 1995, 76: 1283-1293.
30. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995, 10: 378-384.
31. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anesthesiology 1989, 70: 928-934.
32. Jeal W, Benfield P. Transdermal fentanyl. A review of its pharmacological properties and therapeutic efficacy in pain control. Drugs 1997, 53: 109-138.
33. Ahmedzai S, Brooks D. Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage 1997, 13: 254-261.
34. Donner B, Zenz M, Tryba M, Strumpf M. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996, 64: 527-534.
35. Payne R, Mathias SD, Pasta DJ, Wanke LA, Williams R, Mahmoud R. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J Clin Oncol 1998, 16: 1588-1593.
36. Kaiko RF, Fitzmartin RD, Thomas GB, Goldenheim PD. The bioavailability of morphine in controlled-release 30-mg tablets per rectum compared with immediate-release 30-mg rectal suppositories and controlled-release 30-mg oral tablets. Pharmacotherapy 1992, 12: 107-113.
37. Maloney CM, Kesner RK, Klein G, Bockenstette J. The rectal administration of MS Contin: clinical implications of use in end stage cancer. Am J Hosp Care 1989, 6: 34-35.
38. European Association for Palliative Care. Morphine in cancer pain: modes of administration. Expert Working Group of the European Association for Palliative Care. BMJ 1996, 312: 823-826.
39. Simmonds MA. Oral transmucosal fentanyl citrate produces pain relief faster than medication typically used for break-through pain in cancer patients (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997, 16: A180.
40. Hagen NA, Elwood T, Ernst S. Cancer pain emergencies: a protocol for management. J Pain Symptom Manage 1997, 14: 45-50.
41. Coyle N, Cherny NI, Portenoy RK. Subcutaneous opioid infusions at home. Oncology (Huntingt) 1994, 8(4): 21-7; discussion 31-2, 37.
42. Cleary JF. Pharmacokinetic and pharmacodynamic issues in the treatment of breakthrough pain. Semin Oncol 1997, 24(5 Suppl 16): S16-13-9.
43. Lyss AP. Long-term use of oral transmucosal fentanyl citrate (OTFC) for breakthrough pain in cancer patients (Meeting abstract). In: Proc Annu Meet Am Soc Clin Oncol 1997, p A144.
44. Ripamonti C, Bruera E. Current status of patient-controlled analgesia in cancer patients. Oncology (Huntingt) 1997, 11: 373-80, 383-4; discussion 384-386.
45. Paice JA. The phenomenon of analgesic tolerance in cancer pain management. Oncol Nurs Forum 1988, 15: 455-460.
46. Schug SA, Zech D, Grond S, Jung H, Meuser T, Stobbe B. A long-term survey of morphine in cancer pain patients. J Pain Symptom Manage 1992, 7: 259-266.
47. Pies R. Psychotropic medications and the oncology patient. Cancer Pract 1996, 4: 164-166.
48. Browne B, Linter S. Monoamine oxidase inhibitors and narcotic analgesics. A critical review of the implications for treatment. Br J Psychiatry 1987, 151: 210-212.
49. Fallon M, O'Neill B. ABC of palliative care. Constipation and diarrhoea. BMJ 1997, 315(7118): 1293-1296.
50. Vainio A, Ollila J, Matikainen E, Rosenberg P, Kalso E. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995, 346(8976): 667-670.
51. Portenoy RK. Management of common opioid side effects during long-term therapy of cancer pain. Ann Acad Med Singapore 1994, 23(2): 160-170.
52. Wells CJ, Lipton S, Lahuerta J. Respiratory depression after percutaneous cervical anterolateral cordotomy in patients on slow-release oral morphine [letter]. Lancet 1984, 1(8379): 739.
53. Watanabe S, Bruera E. Corticosteroids as adjuvant analgesics. J Pain Symptom Manage 1994, 9(7): 442-445.
54. Devor M, Govrin-Lippmann R, Raber P. Corticosteroids suppress ectopic neural discharge originating in experimental neuromas. Pain 1985, 22(2): 127-137.
55. Sorensen S, Helweg-Larsen S, Mouridsen H, Hansen HH. Effect of high-dose dexamethasone in carcinomatous metastatic spinal cord compression treated with radiotherapy: a randomised trial. Eur J Cancer 1994, 30A(1): 22-27.
56. Twycross R. The risks and benefits of corticosteroids in advanced cancer. Drug Saf 1994, 11(3): 163-178.
57. Ellershaw JE, Kelly MJ. Corticosteroids and peptic ulceration. Palliat Med 1994, 8(4): 313-319.
58. McQuay HJ, Tramer M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain 1996, 68(2-3): 217-227.
59. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995, 311(7012): 1047-1052.
60. Ruskin JN. The cardiac arrhythmia suppression trial (CAST). N Engl J Med 1989, 321(6): 386-388.
61. (CAST) Cardiac Arrhythmia Suppression Trial Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989, 321(6): 406-412.
62. Galer BS, Harle J, Rowbotham MC. Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: a prospective study. J Pain Symptom Manage 1996, 12(3): 161-167.
63. Lipman AG. Analgesic drugs for neuropathic and sympathetically maintained pain. Clin Geriatr Med 1996, 12(3): 501-515.
64. Strang P. Analgesic effect of bisphosphonates on bone pain in breast cancer patients: a review article. Acta Oncol 1996, 5(50): 50-54.
65. Ernst DS, Brasher P, Hagen N, Paterson AH, MacDonald RN, Bruera E. A randomized, controlled trial of intravenous clodronate in patients with metastatic bone disease and pain. J Pain Symptom Manage 1997, 13(6): 319-326.
66. Robinson RG, Preston DF, Schiefelbein M, Baxter KG. Strontium 89 therapy for the palliation of pain due to osseous metastases. JAMA 1995, 274(5): 420-424.
67. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, Lukka H et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993, 25(5): 805-813.
68. Schmeler K, Bastin K. Strontium-89 for symptomatic metastatic prostate cancer to bone: recommendations for hospice patients. Hosp J 1996, 11(2): 1-10.
69. Paulson DF. Oxybutynin chloride in control of post-trasurethral vesical pain and spasm. Urology 1978, 11(3): 237-238.
70. Baert L. Controlled double-blind trail of flavoxate in painful conditions of the lower urinary tract. Curr Med Res Opin 1974, 2(10): 631-635.
71. Abrams P, Fenely R. The action of prostaglandins on smooth muscle of the human urinary tract in vitro. British Journal of Urology 1976, (47): 909-915.
72. Lazzeri M, Beneforti P, Benaim G, Maggi CA, Lecci A, Turini D. Intravesical capsaicin for treatment of severe bladder pain: a randomized placebo controlled study. J Urol 1996, 156(3): 947-952.
73. Barbanti G, Maggi CA, Beneforti P, Baroldi P, Turini D. Relief of pain following intravesical capsaicin in patients with hypersensitive disorders of the lower urinary tract. Br J Urol 1993, 71(6): 686-691.
74. Eckardt VF, Dodt O, Kanzler G, Bernhard G. Treatment of proctalgia fugax with salbutamol inhalation. Am J Gastroenterol 1996, 91(4): 686-689.
75. Boquet J, Moore N, Lhuintre JP, Boismare F. Diltiazem for proctalgia fugax [letter]. Lancet 1986, 1(8496): 1493.
76. Castell DO. Calcium-channel blocking agents for gastrointestinal disorders. Am J Cardiol 1985, 55(3): 210B-213B.
77. Swain R. Oral clonidine for proctalgia fugax. Gut 1987, 28(8): 1039-1040.
78. Patt RB, Proper G, Reddy S. The neuroleptics as adjuvant analgesics. J Pain Symptom Manage 1994, 9(7): 446-453.
79. Hanks GW. Psychotropic drugs. Postgrad Med J 1984, 60(710): 881-885.
80. Ventafridda V, Ripamonti C, Caraceni A, Spoldi E, Messina L, De Conno F. The management of inoperable gastrointestinal obstruction in terminal cancer patients. Tumori 1990, 76(4): 389-393.
81. De Conno F, Caraceni A, Zecca E, Spoldi E, Ventafridda V. Continuous subcutaneous infusion of hyoscine butylbromide reduces secretions in patients with gastrointestinal obstruction. J Pain Symptom Manage 1991, 6(8): 484-486.
82. Baines MJ. ABC of palliative care. Nausea, vomiting, and intestinal obstruction. BMJ 1997, 315(7116): 1148-1150.
83. Baines MJ. Management of intestinal obstruction in patients with advanced cancer. Ann Acad Med Singapore 1994, 23(2): 178-182.
84. Mercadante S. The role of octreotide in palliative care. J Pain Symptom Manage 1994, 9(6): 406-411.
85. Cherny NI, Portenoy RK. Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care 1994, 10(2): 31-38.
86. Burt RA. The Supreme Court speaks - not assisted suicide but a constitutional right to palliative care. N Engl J Med 1997, 337(17): 1234-1236.
87. President's Commission for the Study of Ethical Problems in Medical and Biomedical and Behavioral Research. Deciding to Forgo Life Sustaining Treatment: Ethical and Legal Issues in Treatment Decisions. U.S. Government Printing Office, Washington, 1983.
88. American Medical Association. Good care of the dying patient. Council on Scientific Affairs, American Medical Association. JAMA 1996, 275(6): 474-478.